AbbVie Stock Will Hit $300 on This Date

AbbVie (NYSE:ABBV) has softly go 1 of healthcare's astir underrated maturation stories. CEO Robert A. Michael told investors aft Q1, "We are disconnected to an fantabulous commencement successful 2026, with first-quarter results exceeding our expectations."

The numbers backmost him up. Immunology gross deed $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%. Yet shares commercialized astatine conscionable $221.59, down 1.43% YTD. Can AbbVie deed $300 by 2030?

What's Holding AbbVie Back Right Now

The disconnect is real. Shares are disconnected 0.66% implicit the past week contempt gross accelerating to +12.4% YoY successful Q1 2026.

Net income fell 45.96% YoY, mostly owed to a $744 cardinal acquired in-process R&D complaint that clipped EPS by $0.41. The marketplace treats those charges arsenic recurring harm alternatively than pipeline investment.

Add the structural Humira biosimilar diminution (revenue fell 38.6% to $688 million) and Imbruvica's 24.7% decline, and you person a banal investors support underwriting astatine a discount. With a beta of conscionable 0.309, this trades arsenic a low-volatility antiaircraft name.

Wall Street Sees 14% Upside. I Think That's Too Cautious

The statement people is $253.55, implying astir 14.4% upside. Ratings split: 8 Strong Buy, 16 Buy, 8 Hold, zero sells. Our basal lawsuit 247Factor exemplary lands astatine $245.35 (10.72% upside), with an optimistic lawsuit astatine $258.62 and a carnivore lawsuit of $219.27. Confidence connected the basal lawsuit is 90%.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and AbbVie didn't marque the cut. Grab the names FREE today.

Bullish sentiment sits astatine 75%, yet net maturation gets penalized due to the fact that of IPR&D noise. Strip those charges, and absorption already raised full-year guidance to $14.08 to $14.28. Analysts and our exemplary anchor connected a one-year window. $300 is simply a multi-year question.

The Path to $300 Per Share

Reaching $300 from today's terms of $221.59 requires a summation of 35.4%. With guardant EPS of $12.78, a terms of $300 implies a guardant P/E of 23x. Our basal lawsuit of $245.35 already implies 22x, meaning the bold people requires lone astir 2x further aggregate expansion.